Exciting new research from the Gohil Lab shows that elesclomol, an investigational anti-cancer drug, can be repurposed for the treatment of copper metabolism disorders. This finding published in a recent issue of PNAS is of high biomedical significance as inherited mutations that prevent copper delivery to a critical mitochondrial enzyme result in fatal infantile disorders for which no therapy currently exists. This work led by Shivatheja Soma, a graduate student in Dr. Vishal M. Gohil’s lab, utilized multiple model organisms including yeast, zebrafish, and human patient cell lines to demonstrate the efficacy of elesclomol in rescuing copper-deficient phenotypes. You can learn more about research in the Gohil lab ( and these findings in particular by visiting the following website: